166 related articles for article (PubMed ID: 8813312)
1. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case--control study.
Lumbiganon P; Rugpao S; Phandhu-fung S; Laopaiboon M; Vudhikamraksa N; Werawatakul Y
Br J Obstet Gynaecol; 1996 Sep; 103(9):909-14. PubMed ID: 8813312
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study.
Ikomi AA; Singer A
Br J Obstet Gynaecol; 1997 Mar; 104(3):385-6. PubMed ID: 9091025
[No Abstract] [Full Text] [Related]
3. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study.
Wilailak S; Vipupinyo C; Suraseranivong V; Chotivanich K; Kietpeerakool C; Tanapat Y; Therasakvichya S; Hamontri S; Linasmita V; Bunyapipat S; Chindavijak S; Ittiwisavakul K; Khemapech N; Suekwattana P; Thanapprapasr D; Lumbiganon P
BJOG; 2012 May; 119(6):672-7. PubMed ID: 22489761
[TBL] [Abstract][Full Text] [Related]
4. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Int J Cancer; 1991 Sep; 49(2):186-90. PubMed ID: 1831802
[TBL] [Abstract][Full Text] [Related]
5. Cervical cancer risk and use of depot-medroxyprogesterone acetate in Costa Rica.
Oberle MW; Rosero-Bixby L; Irwin KL; Fortney JA; Lee NC; Whatley AS; Bonhomme MG
Int J Epidemiol; 1988 Dec; 17(4):718-23. PubMed ID: 2976059
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Lancet; 1991 Oct; 338(8771):833-8. PubMed ID: 1681212
[TBL] [Abstract][Full Text] [Related]
7. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Thomas DB; Ray RM
Contraception; 1995 Nov; 52(5):307-12. PubMed ID: 8585888
[TBL] [Abstract][Full Text] [Related]
8. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Int J Cancer; 1991 Sep; 49(2):191-5. PubMed ID: 1831803
[TBL] [Abstract][Full Text] [Related]
9. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
Kaunitz AM
J Reprod Med; 1996 May; 41(5 Suppl):419-27. PubMed ID: 8725705
[TBL] [Abstract][Full Text] [Related]
10. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
[TBL] [Abstract][Full Text] [Related]
11. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Contraception; 1992 Apr; 45(4):299-312. PubMed ID: 1387601
[TBL] [Abstract][Full Text] [Related]
12. Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Int J Cancer; 1991 Sep; 49(2):182-5. PubMed ID: 1831801
[TBL] [Abstract][Full Text] [Related]
13. Depot medroxyprogesterone acetate and breast cancer. A review of current knowledge.
Chilvers CE
Drug Saf; 1996 Sep; 15(3):212-8. PubMed ID: 8879975
[TBL] [Abstract][Full Text] [Related]
14. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
Pardthaisong T; Gray RH; McDaniel EB
Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
[TBL] [Abstract][Full Text] [Related]
15. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
[TBL] [Abstract][Full Text] [Related]
17. Invasive cervical cancer and depot-medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Thomas DB; Noonan L; Whitehead A; Roseman D
Bull World Health Organ; 1985; 63(3):505-11. PubMed ID: 2931205
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study.
Bassaw K; Gangar K
Br J Obstet Gynaecol; 1997 Jun; 104(6):758-9. PubMed ID: 9197894
[No Abstract] [Full Text] [Related]
19. Bone density in long term users of depot medroxyprogesterone acetate.
Gbolade B; Ellis S; Murby B; Randall S; Kirkman R
Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421
[TBL] [Abstract][Full Text] [Related]
20. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
Upadhyay UD; Zlidar VM; Foster DG
Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
